CTK Biotech’s Single-Use COVID-19 Antigen Self-Test Receives CE Mark
By LabMedica International staff writers Posted on 04 Nov 2021 |
CTK Biotech, Inc. (Poway, CA, USA) has obtained the CE mark for its OnSite COVID-19 Ag Self Test and will begin shipping the new test to the countries that accept the CE mark this month.
The OnSite COVID-19 Ag Self Test is a single-use lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swab specimens from individuals suspected of COVID-19. The test is designed for use with self-collected samples within the first seven days post-onset of symptoms, as an aid in identifying SARS-CoV-2 infection. The easy-to-use test screens for COVID-19 in 15 to 20 minutes and uses nasal swab for ease of use and minimizing discomfort. The OnSite COVID-19 Ag Self-Test comes with two individually sealed test kits.
With over 20 years in infectious disease diagnostics, CTK has manufactured a line-up of professional use COVID-19 diagnostic tools. In addition to the OnSite COVID-19 Ag Self Test, the company also offers the OnSite COVID-19 Ag Rapid Test that detects the presence of antigens from the SARS-CoV-2 virus, namely the viral Nucleocapsid Protein (NP). The OnSite COVID-19 Ag Rapid Test can detect the NP mutants with mutations from the UK, South Africa, and Brazil variants.
In August this year, the company had launched the Aridia COVID-19 Real-Time PCR Test for the specific and qualitative detection of the novel coronavirus SARS-CoV-2, responsible for COVID-19, in respiratory specimens. The test targets the conserved regions of the SARS-CoV-2 ORF1ab and N genes using specific primers and fluorescently labeled probes. The test can detect the SARS-CoV-2 UK, South Africa, Brazil, California, Nigeria, and India (Delta) variants. Furthermore, as the Aridia COVID-19 Real-Time PCR Test detects two SARS-CoV-2 targets, its performance is less susceptible to the effects of variants than tests designed to detect a single target.
Related Links:
CTK Biotech, Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants